PA
ABCL icon

Parallel Advisors’s AbCellera Biologics ABCL Stock Holding History

Parallel Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.6K Buy
4,029
+514
+15% +$2.51K ﹤0.01% 2410
2026
Q1 		$12.3K Buy
3,515
+120
+4% +$432 ﹤0.01% 2661
2025
Q4 		$11.6K Buy
3,395
+687
+25% +$3.07K ﹤0.01% 2546
2025
Q3 		$13.6K Buy
2,708
+20
+0.7% +$88 ﹤0.01% 2418
2025
Q2 		$9.22K Sell
2,688
-631
-19% -$1.57K ﹤0.01% 2509
2025
Q1 		$7.4K Buy
3,319
+223
+7% +$640 ﹤0.01% 2550
2024
Q4 		$9.07K Buy
3,096
+1,098
+55% +$3.06K ﹤0.01% 2440
2024
Q3 		$5.2K Buy
1,998
+893
+81% +$2.47K ﹤0.01% 2597
2024
Q2 		$3.27K Sell
1,105
-1,363
-55% -$5.16K ﹤0.01% 2654
2024
Q1 		$11.2K Hold
2,468
– – ﹤0.01% 2257
2023
Q4 		$14.1K Buy
2,468
+1,930
+359% +$8.95K ﹤0.01% 2135
2023
Q3 		$2.48K Buy
538
+114
+27% +$694 ﹤0.01% 2748
2023
Q2 		$2.74K Buy
424
+123
+41% +$839 ﹤0.01% 2660
2023
Q1 		$2.27K Buy
301
+122
+68% +$1.11K ﹤0.01% 2720
2022
Q4 		$1.81K Buy
+179
New +$2.07K ﹤0.01% 2717

Other funds holding ABCL

TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CMF
Counterpoint Mutual Funds San Diego, California $1.01B AUM 37.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.11B AUM 38.73% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
DRP
Decker Retirement Planning Levi, Utah $294M AUM 97.44% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return
CFG
Citizens Financial Group Providence, Rhode Island $8.3B AUM 27.66% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Parallel Advisors's ABCL Position: Q2 2026 in Review

Parallel Advisors increased its AbCellera Biologics (ABCL) stake by 15% in Q2 2026, buying an estimated $2.51K and bringing the position to 4,029 shares worth $31.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2410.

Parallel Advisors first reported a position in ABCL in Q4 2022 and has held it in 15 quarters since. 62 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Parallel Advisors held 4,029 shares of AbCellera Biologics worth $31.6K as of Q2 2026.
  • Parallel Advisors bought 514 AbCellera Biologics shares in Q2 2026, an estimated $2.51K.
  • AbCellera Biologics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2410 holding.
  • Parallel Advisors first reported a position in AbCellera Biologics in Q4 2022 and has held it in 15 quarters since.
  • 62 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.